Skindex-29 (Skin Disease Quality of Life Instrument)
Skindex-29 Skin Disease Quality of Life Instrument · Also known as: Skindex, Skindex-QoL
Skindex-29 is a validated, patient-centered quality-of-life measure specifically designed to assess the impact of any skin disease on patients' symptoms, emotions, and functioning. Developed by Chren, Lasek, and colleagues in 1997, it captures the multidimensional burden of dermatological conditions beyond clinical severity. Skindex-29 is widely used in clinical trials, observational studies, and dermatology practice to ensure that treatment efficacy encompasses quality-of-life outcomes.
Read the full method
Sign in with a free account to read this section.
Method map
The neighbourhood of related methods — select a node to explore.
When to use it
Skindex-29 is appropriate for any patient with a skin disease, regardless of severity or clinical type. It is particularly valuable in trials of conditions with high quality-of-life burden (acne, atopic dermatitis, psoriasis, alopecia, vitiligo, ichthyosis) to ensure treatment efficacy encompasses not only clinical improvement but emotional and functional benefit. Skindex-29 is also used in observational studies to quantify disease burden in specific populations and to identify patients at high risk of depression or social isolation. In clinical practice, periodic Skindex-29 assessment (baseline, 8–12 weeks, 6 months) helps identify patients whose quality of life is not improving despite objective clinical progress and may indicate need for psychological support or therapy adjustment.
Strengths & limitations
- Patient-centered; directly captures impact on emotions, functioning, and daily symptoms rather than clinical signs.
- Multidimensional; three subscales enable nuanced understanding of which QoL domains are most affected.
- Broadly applicable; validated across all major skin diseases (eczema, psoriasis, acne, alopecia, vitiligo) and diverse populations.
- Responsive to treatment; sensitive to clinically meaningful change with both topical and systemic therapies.
- Practical; brief (29 items, 5–10 minutes) self-administered format suitable for routine clinical use and trials.
- Validated translations available in 15+ languages.
- Strong psychometric properties: internal consistency, test-retest reliability, construct validity.
- Emotional subscale particularly sensitive in conditions with psychological burden (acne, alopecia).
- Subjective recall; patients' memory of QoL impact over the past month may vary with current mood or recent events.
- No clinician-rated version; cannot be completed by proxy (unlike DLQI variants for young children).
- Ceiling effects possible in very mild disease; patients with minimal QoL impact may score near zero across all items.
- Does not capture objective disease severity; a patient with severe psoriasis but high coping may score lower than a patient with mild disease and high distress.
- Symptom items focus on subjective perception (itching, burning) rather than objective clinical signs; does not replace clinical assessment.
- Recall period of 'past month' is fixed; adaptation for different assessment intervals is not formally validated.
Frequently asked
Should Skindex-29 be used alongside PASI, EASI, or SCORAD in trials?
Yes. Objective clinical measures (PASI, EASI, SCORAD) and quality-of-life measures (Skindex-29, DLQI) are complementary. Many modern trials use both as co-primary or primary + secondary endpoints. This ensures treatments are evaluated not only for clinical efficacy but for meaningful improvement in patients' daily lives and emotional well-being.
What is the MCID for Skindex-29?
A change of ≥8 points on any Skindex-29 subscale (out of 100) is considered clinically meaningful improvement. For the overall Skindex-29 score, an 8-point reduction (out of 100) indicates improvement. Always report baseline and endpoint scores, as well as percentage change, to contextualize meaningfulness.
How does Skindex-29 compare to DLQI (Dermatology Life Quality Index)?
Both measure QoL impact in dermatological disease. DLQI has 10 items and focuses on functioning and social impact. Skindex-29 has 29 items and provides more granular assessment of symptoms, emotions, and functioning separately. For clinical trials, DLQI is often preferred for brevity; for detailed QoL assessment, Skindex-29 is superior. Choose based on study goals and respondent burden tolerance.
Can Skindex-29 be completed by parents for children?
The original Skindex-29 is not validated for proxy completion. However, for children aged 8+, direct self-administration is typically feasible. For younger children, the Skindex-Child variant (if available) is preferred. Always verify language level and reading comprehension; simplified versions may be needed for children under age 10.
How should high Skindex-29 scores be interpreted clinically?
High scores (>50) indicate substantial QoL burden and warrant psychological assessment and possible referral for mental health support in addition to dermatological treatment. Do not assume clinical treatment escalation alone will resolve QoL impact; assess for depression, anxiety, and social isolation.
Sources
- Chren MM, Lasek RJ, Quinn LM, et al. Skindex, a quality-of-life measure for patients with skin disease: reliability, validity, and responsiveness. J Invest Dermatol. 1997;107(5):707-713. DOI: 10.1111/1523-1747.ep12365600 ↗
- Chren MM, Lasek RJ, Flocke SA, Zyzanski SJ. Improved discriminative and evaluative capability of a refined version of Skindex, a quality-of-life instrument for patients with skin diseases. Arch Dermatol. 1997;133(11):1433-1440. DOI: 10.1001/archderm.133.11.1433 ↗
How to cite this page
ScholarGate. (2026, June 3). Skindex-29 Skin Disease Quality of Life Instrument. ScholarGate. https://scholargate.app/en/dermatology/skindex-29
Which method?
Set this method beside its closest kin and read them side by side — the library lays the books on the table; the choice is yours.
Compare side by side →